跳至主要内容
临床试验/NCT05670678
NCT05670678已完成不适用

Improved Respiratory Infection Outcomes Associated With Lactoferrin Fortified a2 Growing up Formula Consumption in Children of 2 to 3 Year Old: a Randomized, Open Label Trial

a2 Milk Company Ltd.2 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2022年12月19日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
200
试验地点
2
主要终点
Change of frequency of acute respiratory infection (ARI) and/or diarrheal disease

研究概览

简要总结

The goal of this observational study is to compare the incidence of ARI and/or diarrheal disease associated with feeding different formulas with and without lactoferrin supplement in children of 2-3 years old. 200 children eligible for the study will be enrolled from two study sites and randomly assigned to two groups (a2 growing up stage 3 formula puls lactoferrin supplement, and Enfinitas growing up stage 3 formula) to feed for 90 days. About 160 children (80 for each group) are expected to finish the study, and data will be collected during the four visits across the study.

Researchers will compare the two groups to see if there is significant decrease of the occurrence of diarrheal disease and/or acute respiratory infection for children fed with a2 growing up stage 3 formula puls lactoferrin supplement

详细描述

This study is two arms, opening parallel-designed, observational study. Diarrheal and infectious episodes, including acute upper and lower respiratory infections (ARI), changes in stool patterns, use of systemic antibiotics, adverse events and study formula consumption will be compared in children 2 - 3 years of age who are assigned to receive one of the two following study formulas for a 3-month feeding period: a2 growing up stage 3 formula puls lactoferrin supplement and Enfinitas growingup stage 3 formula.

200 children eligible for the study will be enrolled from two study sites and randomly assigned to two groups to feed for 90 days. About 160 children (80 for each group) are expected to finish the study, and data of primary and secondary outcomes will be collected during the four visits across the study. A sample size of 80 completed per group is needed to achieve a 80% power.

The Andersen-Gill model will be used to model the primary outcome (recurrent event of either diarrheal disease or an acute respiratory infection) under the framework of the proportional hazard assumption. For other secondary outcomes such as duration of acute respiratory infections(ARI) and/or diarrheal disease, episodes of systemic antibiotic use,amount of study formula consumed,changes in stool pattern and cost of treatment will also be analyzed.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
2 Years 至 3 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Full term born children current aged 2-3 years old
  • Birth weight not less than 2500g (5lb 8oz)
  • Consumes Milk or milk-based beverage regularly before recruitment
  • Informed consent signed
  • Parents or guardians of the infants committ not to participate in interventional clinical research during the intervention

排除标准

  • Has a potential risk of metabolic or chronic disease; Fetal malformation; Or present with condition(s) that the investigator believes may affect the infant's ability to be orally fed, the infant's normal growth/development, or the infant's health evaluation.
  • In-take prebiotics or probiotic continuesly 15 days before the recruitment.
  • Growth problems or other protencial risks.
  • Larger-gestational age (LGA) babies born to mothers with gestational diabetes (defined as newborns whose birth weight is above the 90th percentile of average - Treated with antibiotics 7 days before study intervention.

结局指标

主要结局

Change of frequency of acute respiratory infection (ARI) and/or diarrheal disease

时间窗: baseline day 0, day 90

Change of frequency of acute respiratory infection (ARI) and/or diarrheal disease from baseline to 3 months

次要结局

  • Changes in stool pattern(baseline day 0, visit 1 day 30, visit 2 day 60, visit 4 day 90)
  • Amount of study formula consumed(baseline day 0, visit 1 day 30, visit 2 day 60, visit 4 day 90)
  • Cost of medical treatment(baseline day 0, visit 1 day 30, visit 2 day 60, visit 4 day 90)
  • Duration of acute respiratory infections(ARI) and/or diarrheal disease(baseline day 0, visit 1 day 30, visit 2 day 60, visit 4 day 90)
  • Number of days of antibiotics treated(baseline day 0, visit 1 day 30, visit 2 day 60, visit 4 day 90)

研究者

发起方
a2 Milk Company Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Improved Respiratory Infection by Consuming... | 临床试验